Skip to main
ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics (ARQT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Arcutis Biotherapeutics Inc. has demonstrated strong financial performance, with its product candidate ZORYVE achieving total sales of $99.2 million in Q3 2025, representing a 22% increase quarter-over-quarter and a remarkable 122% year-over-year growth, surpassing expectations substantially. The company's successful completion of pivotal Phase 3 trials for ZORYVE in plaque psoriasis, combined with recent collaboration efforts and label expansions, are anticipated to drive continued sales momentum into 2026, with an initial guidance projecting revenues between $455 million and $470 million. Additionally, the company's reporting of positive net income for the first time further underscores its advancing operational efficiency and financial stability in the evolving medical dermatology market.

Bears say

Arcutis Biotherapeutics Inc. maintains expectations for cash flow break-even in 2026 and projected net product sales of $455 million to $470 million, despite potential risks from the end of a co-promotion agreement. However, the company closed the third quarter of 2025 with approximately $191 million in cash, reflecting a decline in net operating cash, which raises concerns about its financial stability. Additionally, reliance on third-party supplier Interquim for Zoryve’s manufacturing and significant operating expenses associated with the development of its pipeline candidates pose further risks to the company's financial outlook.

Arcutis Biotherapeutics (ARQT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcutis Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcutis Biotherapeutics (ARQT) Forecast

Analysts have given Arcutis Biotherapeutics (ARQT) a Buy based on their latest research and market trends.

According to 5 analysts, Arcutis Biotherapeutics (ARQT) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcutis Biotherapeutics (ARQT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.